Active Ingredient History
Trans-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid (also known as Fluciclovine (18F)) was approved under brand name AXUMIN as a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence. Besides, this radioactive compound is used in patients with cervical, ovarian epithelial or endometrial cancers. Fluciclovine F 18 is a synthetic amino acid transported across mammalian cell membranes by amino acid transporters, such as LAT-1 and ASCT2, which are upregulated in prostate cancer cells, but as was shown, this compound has a higher affinity for ASCT2 in comparison with other transporters. NCATS
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Prostatic Neoplasms (approved 2016)
Brain Neoplasms (Phase 3)
Breast Neoplasms (Phase 1)
Carcinoma, Ovarian Epithelial (Phase 4)
Carcinoma, Transitional Cell (Phase 1)
Endometrial Neoplasms (Phase 4)
Glioblastoma (Phase 2)
Glioma (Early Phase 1)
Graft Rejection (Phase 1)
Lung Neoplasms (Phase 1)
Neoplasm Metastasis (Phase 1)
Neoplasms (Phase 2)
Neoplasms, Germ Cell and Embryonal (Phase 2)
Pancreatitis, Graft (Early Phase 1)
Prostatic Neoplasms (Phase 4)
Squamous Cell Carcinoma of Head and Neck (Phase 1)
Testicular Diseases (Phase 2)
Testicular Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Early Phase 1)
Uterine Cervical Neoplasms (Phase 4)
Uterine Neoplasms (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue